AntiviralGeneral AntiviralPositive observation
Record detail Table 1: G54-LNA EC50/IC50 <0.5 µM (EMSA).
- Measure
- EC50
- Value
- <0.5 µM (EMSA)
- Target
- SARS-CoV-2
- Assay
- Not reported by source
Back to Evidence
Paper-scoped peptide mentionSequence not reported or unresolved
G54-LNA
PMC10668963::PEP000003
Source publication
Unwinding the SARS-CoV-2 Ribosomal Frameshifting Pseudoknot with LNA and G-Clamp-Modified Phosphorothioate Oligonucleotides Inhibits Viral Replication
Biomolecules · 2023
- Sequence status
- not reported or unresolved
- Standardization
- Sequence unresolved
- Source location
- unknown
- Activity records
- 4
Sequence evidence
Reported molecular identity
The publication reports a peptide label or compound identity, but no sequence could be safely standardized from the available text, table, figure, or structure context.
Table 1: G54-LNA EC50/IC50 <0.5 µM (EMSA).
Experimental observations
Records linked to this mention
AntiviralGeneral AntiviralPositive observation
Record detail Table 1: G54-LNA EC50/IC50 26 ± 9 nM (DLA).
- Measure
- other
- Value
- 26 ± 9 nM (DLA)
- Target
- HEK-293T
- Assay
- Not reported by source
AntiviralGeneral AntiviralPositive observation
Record detail Section 3.3: 'The IC50 values were equal to 50 ± 30 nM (G54-LNA)' in HEK-293T-ACE2 cells.
- Measure
- other
- Value
- 50 ± 30 nM
- Target
- HEK-293T-ACE2
- Assay
- Not reported by source
AntiviralGeneral AntiviralPositive observation
Record detail Section 3.3: 'The IC50 values were equal to 15 ± 5 nM (G54-LNA)' in GBM6138 cells.
- Measure
- other
- Value
- 15 ± 5 nM
- Target
- GBM6138
- Assay
- Not reported by source
Local peptide labels such as P1, PEP1, or peptide 1 are grouped only within this paper and are not assumed to represent the same molecule across publications.